Comments
About two months after launching novel anti-diabetic drug Remogliflozin etabonate (Remogliflozin) in India, global drug firm Glenmark Pharmaceuticals Ltd on Thursday inked an agreement with Indian pharma major Torrent Pharmaceuticals Limited to co-market the drug in the country.
In a joint statement, Torrent and Glenmark said that they have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin Etabonate in India.
Under the terms of the agreement, Glenmark will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent.
Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ brand in India.
Remogliflozin is an innovative, patent-protected SGLT2 inhibitor indicated in treatment of Type-2 Diabetes Mellitus in adults.
SGLT2 inhibitors are cutting-edge, globally-accepted latest class of oral anti-diabetes drugs that provide glycemic control, induce weight loss and reduce cardiovascular risks.
In April, Glenmark had become the first-ever company to launch Remogliflozin, thereby making India the first country to get access to the drug.
The Drugs Controller General of India (DCGI) had granted an approval to Glenmark for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin.
Remogliflozin is the only SGLT2 inhibitor to be manufactured in India from active pharmaceutical ingredient (API) to formulation.
“The burden of diabetes in India is growing at an alarming rate and through this collaboration, we aim to improve access to the latest, novel and globally-researched SGLT2 inhibitor by providing an effective, high quality and world-class treatment option to patients in India,” said Sujesh Vasudevan, President, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals.
“This partnership will also lay the foundation for a long-term collaboration with Torrent for Remogliflozin in terms of its additional line extensions and further clinical development,” Vasudevan added..
Dhruv Gulati, Executive Director (India & ROW), Torrent Pharma, said: “The drug will augment the Type-2 Diabetes Mellitus treatment armamentarium in the country and this partnership will be an important step towards enhancing access to the growing needs of diabetic patients."
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.